PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10660118-1	2000	The site of interaction for the 1-(3",4",5"-trimethoxybenzyl) group of trimetoquinol (TMQ) with beta-adrenoceptors (beta-ARs) is important for the rational design of highly potent and beta3-AR-selective analogs.	Tretoquinol	71-84	adrenoceptor beta 3	Homo sapiens	184-192	
11150922-4	2001	The 3",5"-diiodo-4"-amino analog of TMQ was the most potent beta(3)-AR agonist, 17-fold more potent at the beta(3)-AR versus the beta(1)-AR.	Tretoquinol	36-39	adrenoceptor beta 3	Homo sapiens	60-70	
11150922-4	2001	The 3",5"-diiodo-4"-amino analog of TMQ was the most potent beta(3)-AR agonist, 17-fold more potent at the beta(3)-AR versus the beta(1)-AR.	Tretoquinol	36-39	adrenoceptor beta 3	Homo sapiens	107-117	
11150922-5	2001	Masking of the 6,7-dihydroxy group of the catechol ring of 3",5"-diiodo-4"-acetamido analog of TMQ, a potent beta(1)- and beta(3)-AR agonist, abolished activity at both beta-AR subtypes.	Tretoquinol	95-98	adrenoceptor beta 3	Homo sapiens	122-132	
11150922-6	2001	Furthermore, substitution of a strong electron withdrawing group such as the trifluoromethyl moiety at the 1-benzyl ring of TMQ dramatically decreased potency at beta(1)- and beta(3)-AR compared to TMQ.	Tretoquinol	124-127	adrenoceptor beta 3	Homo sapiens	175-185	
11150922-8	2001	Our results define the structural and electronic properties of substituents on TMQ necessary for potent activation of beta(1)- and beta(3)-AR and suggest that further modifications of the 1-benzyl iodine-substituted analogs may yield potent beta(3)-AR agonists.	Tretoquinol	79-82	adrenoceptor beta 3	Homo sapiens	131-141	
11150922-8	2001	Our results define the structural and electronic properties of substituents on TMQ necessary for potent activation of beta(1)- and beta(3)-AR and suggest that further modifications of the 1-benzyl iodine-substituted analogs may yield potent beta(3)-AR agonists.	Tretoquinol	79-82	adrenoceptor beta 3	Homo sapiens	241-251	
10660118-1	2000	The site of interaction for the 1-(3",4",5"-trimethoxybenzyl) group of trimetoquinol (TMQ) with beta-adrenoceptors (beta-ARs) is important for the rational design of highly potent and beta3-AR-selective analogs.	Tretoquinol	86-89	adrenoceptor beta 3	Homo sapiens	184-192	
10660118-4	2000	A similar rank order of binding affinities (K(i) approximately 0.11 to 2.5 microM) and potencies (K(act) approximately 0.45 to 9.5 nM) was obtained for TMQ analogs on the human beta3-AR.	Tretoquinol	152-155	adrenoceptor beta 3	Homo sapiens	177-185	
10660118-9	2000	Thus, the lipophilic 1-benzyl ring of TMQ analogs interacts with a hydrophobic region of the beta-AR that may represent an exo-site or an allosteric binding site.	Tretoquinol	38-41	adrenoceptor beta 3	Homo sapiens	93-100	
10691685-1	2000	Trimetoquinol (1, TMQ) is a potent nonselective beta-adrenergic receptor (AR) agonist and a thromboxane A(2)/prostaglandin endoperoxide (TP) receptor antagonist, while 3",5"-diiodo-TMQ (2) exhibits beta(3)-AR selectivity.	Tretoquinol	0-13	adrenoceptor beta 3	Homo sapiens	198-208	
10377236-2	1999	Replacement of the catechol moiety of TMQ with a 2-aminothiazole group resulted in novel thiazolopyridine derivatives 9-11 which have been synthesized and evaluated for biological activity on human beta1-, beta2-, and beta3-AR.	Tretoquinol	38-41	adrenoceptor beta 3	Homo sapiens	218-226	
10525112-2	1999	In cAMP accumulation assays, (-)-TMQ was 214-, 281-, and 776-fold more potent than (+)-TMQ at stimulating beta(1)-, beta(2)-, and beta(3)-adrenoceptor subtypes, respectively.	Tretoquinol	29-36	adrenoceptor beta 3	Homo sapiens	116-150	
10525112-2	1999	In cAMP accumulation assays, (-)-TMQ was 214-, 281-, and 776-fold more potent than (+)-TMQ at stimulating beta(1)-, beta(2)-, and beta(3)-adrenoceptor subtypes, respectively.	Tretoquinol	83-90	adrenoceptor beta 3	Homo sapiens	116-150	
10525112-3	1999	In radioligand binding assays, (-)-TMQ exhibited 123-, 331-, and 5-fold greater affinity than (+)-TMQ for beta(1)-, beta(2)-, and beta(3)-adrenoceptor subtypes, respectively.	Tretoquinol	31-38	adrenoceptor beta 3	Homo sapiens	116-150	
10525112-3	1999	In radioligand binding assays, (-)-TMQ exhibited 123-, 331-, and 5-fold greater affinity than (+)-TMQ for beta(1)-, beta(2)-, and beta(3)-adrenoceptor subtypes, respectively.	Tretoquinol	94-101	adrenoceptor beta 3	Homo sapiens	116-150	
10525112-4	1999	(-)-TMQ and (+/-)-TMQ activated the human beta(3)-adrenoceptor with an 8.2- and 3.4-fold greater efficacy, respectively, than the reference beta-adrenoceptor agonist (-)-isoproterenol (efficacy = 1).	Tretoquinol	0-7	adrenoceptor beta 3	Homo sapiens	42-62	
10525112-4	1999	(-)-TMQ and (+/-)-TMQ activated the human beta(3)-adrenoceptor with an 8.2- and 3.4-fold greater efficacy, respectively, than the reference beta-adrenoceptor agonist (-)-isoproterenol (efficacy = 1).	Tretoquinol	12-21	adrenoceptor beta 3	Homo sapiens	42-62	
10525112-5	1999	The 3",5"-diiodo analogs of TMQ were partial agonists of the beta(2)-adrenoceptor relative to (-)-isoproterenol, and their potencies were 5- to 10-fold higher at the beta(3)-adrenoceptor as compared with beta(1)-adrenoceptors.	Tretoquinol	28-31	adrenoceptor beta 3	Homo sapiens	166-186	
10525112-7	1999	Furthermore, the 3",5"-diiodo-4"-methoxybenzylTHP derivative of TMQ was 65-fold more potent than the corresponding 3",4",5"-trimethoxybenzylTHP at the human beta(3)-adrenoceptor.	Tretoquinol	64-67	adrenoceptor beta 3	Homo sapiens	157-177	
10525112-8	1999	Our results indicate that 6, 7-dihydroxy-catechol-modified and 1-benzyl halogen-substituted derivatives of TMQ represent promising leads for the development of beta(3)-adrenoceptor-selective agonists.	Tretoquinol	107-110	adrenoceptor beta 3	Homo sapiens	160-180